A share price of CRISPR Therapeutics AG [CRSP] is currently trading at $74.50, up 2.14%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CRSP shares have gain 3.46% over the last week, with a monthly amount drifted -9.60%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 13, March 2024, CRISPR Therapeutics Proposes New Appointment to the Board of Directors. In a post published today on Yahoo Finance, CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced it proposes to elect Christian Rommel, Ph.D., to its Board of Directors at the Company’s annual general meeting to be held this year.
From an analyst’s perspective:
Previously, TD Cowen downgraded its rating to Underperform on December 11, 2023, and kept the price target unchanged to $30. On October 17, 2023, downgrade downgraded it’s rating to Neutral. Mizuho started tracking the stock assigning a Buy rating and suggested a price target of $82 on September 27, 2023. Citigroup upgraded its rating to a Buy. William Blair started tracking with a Outperform rating for this stock on May 30, 2023, and assigned it a price target of $75. In a note dated April 13, 2023, Cantor Fitzgerald initiated an Overweight rating and provided a target price of $72 on this stock.
CRISPR Therapeutics AG experienced fluctuations in its stock price throughout the past year between $37.55 and $91.10. Currently, Wall Street analysts expect the stock to reach $130.69 within the next 12 months. CRISPR Therapeutics AG [NASDAQ: CRSP] shares were valued at $74.50 at the most recent close of the market. An investor can expect a potential return of 75.42% based on the average CRSP price forecast.
Analyzing the CRSP fundamentals
Trailing Twelve Months sales for CRISPR Therapeutics AG [NASDAQ:CRSP] were 371.21M which represents 3353333.33% growth. Gross Profit Margin for this corporation currently stands at 0.65% with Operating Profit Margin at -0.6%, Pretax Profit Margin comes in at -0.41%, and Net Profit Margin reading is -0.42%. To continue investigating profitability, this company’s Return on Assets is posted at -0.07, Equity is -0.08 and Total Capital is -0.1. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.13.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 73.15 points at the first support level, and at 71.80 for the second support level. However, for the 1st resistance point, the stock is sitting at 75.88, and for the 2nd resistance point, it is at 77.26.
CRISPR Therapeutics AG [CRSP] reported earnings per share of $1.1 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.07/share, meaning a difference of $1.17 and a surprise factor of 1,671.40%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$1.41 per share as compared to estimates of -$1.95 per share, a difference of $0.54 representing a surprise of 27.70%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for CRISPR Therapeutics AG [NASDAQ:CRSP] is 17.54. Further, the Quick Ratio stands at 17.54, while the Cash Ratio is 3.58. Considering the valuation of this stock, the price to sales ratio is 16.90, the price to book ratio is 3.17.
Transactions by insiders
Recent insider trading involved Kulkarni Samarth, Chief Executive Officer, that happened on Mar 15 ’24 when 20000.0 shares were sold. Chief Financial Officer, Prasad Raju completed a deal on Mar 15 ’24 to sell 3524.0 shares. Meanwhile, Chief Executive Officer Kulkarni Samarth sold 4583.0 shares on Mar 12 ’24.
